Merck After Vioxx: No Merger, But No Big Near-Term Launches
Executive Summary
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed
You may also be interested in...
Celebrex Gets Committee Nod For Juvenile Arthritis, But Safety Registry Urged
Concerns about cardiovascular risks associated with COX-2 inhibitors continue to haunt Pfizer's Celebrex as FDA's Arthritis Advisory Committee asked for long-term safety data as a condition of celecoxib's approval for a pediatric indication
Celebrex Gets Committee Nod For Juvenile Arthritis, But Safety Registry Urged
Concerns about cardiovascular risks associated with COX-2 inhibitors continue to haunt Pfizer's Celebrex as FDA's Arthritis Advisory Committee asked for long-term safety data as a condition of celecoxib's approval for a pediatric indication
Merck’s Vioxx Conduct Receives Passing Grade In Review By Outside Firm
An independent report contracted by Merck has concluded that the company's senior executives did not mishandle the development, testing and marketing of Vioxx (rofecoxib), despite the fact that the product is widely viewed as one of the more significant debacles in pharmaceutical history